These peptides provide highly effective treatment options for type 2 diabetes mellitus and obesity, but their current reliance on subcutaneous injection can adversely affect adherence, particularly during long-term therapy
Do you serve patients Nationally
Clinical Pharmacology of GLP-1 RAs The approval of the first GLP-1 RA, exenatide, by the FDA in 2005 marked a significant advancement in treating diabetes and obesity
To improve their reproducibility, studies need to use uniform clinical and research criteria, standardise sample collection, and use thorough statistical analyses (305)
Clinicians should apply clinical judgement to select an individualised approach and may choose between: A one-to-two-week washout before semaglutide initiation, which is preferred for patients with significant side effects
The medication also reduces the frequency of food cravings